Success Metrics

Completion Rate
0%(0/4)
Active Trials
0(0%)
Terminated
4(100%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 4 finished

Non-Completion Rate

100.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(4)

Detailed Status

Terminated4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

terminated4100%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_1

A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

NCT05590377
terminatedphase_1

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

NCT05556616
terminatedphase_1

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT03215030
terminatedphase_1

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

NCT04157517

Clinical Trials (4)

Showing 4 of 4 trials
NCT05590377Phase 1

A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Terminated
NCT05556616Phase 1

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Terminated
NCT03215030Phase 1

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Terminated
NCT04157517Phase 1

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4